California State Teachers Retirement System Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

California State Teachers Retirement System lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 935,928 shares of the medical research company’s stock after acquiring an additional 178 shares during the quarter. California State Teachers Retirement System’s holdings in Edwards Lifesciences were worth $69,287,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $26,000. Millstone Evans Group LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.0 %

Shares of EW opened at $76.28 on Wednesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $44.84 billion, a P/E ratio of 10.94, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company’s 50-day moving average price is $70.99 and its 200 day moving average price is $71.20. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the business posted $0.66 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EW shares. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Robert W. Baird increased their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Finally, Piper Sandler raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $73.00 to $80.00 in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.45.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.